MFM-223Homo sapiens (Human)Cancer cell line

Also known as: MFM223

🤖 AI SummaryBased on 8 publications

Quick Overview

Human breast cancer cell line used in cancer research.

Detailed Summary

MFM-223 is a human breast cancer cell line derived from pleural effusion, commonly used in cancer research for studying tumor progression and therapeutic responses. It is part of a panel of cell lines used to analyze proteomic and transcriptomic profiles, contributing to understanding of molecular mechanisms in breast cancer. The cell line has been utilized in studies involving gene expression, protein signatures, and drug sensitivity assays, providing insights into cancer biology and potential treatment strategies.
Generated on 6/17/2025

Basic Information

Database IDCVCL_1408
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age CategoryAdult
SexFemale
Subtype Featuresluminal ER, PR+

Disease Information

DiseaseBreast carcinoma
LineageBreast
SubtypeBreast Invasive Ductal Carcinoma
OncoTree CodeIDC

DepMap Information

Source TypeDSMZ
Source IDACH-001819_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Lys132Arg (c.395A>G)Unspecified-PubMed=34732238
MutationSimplePIK3CAp.His1047Arg (c.3140A>G)Unspecified-PubMed=25926053, PubMed=20570890

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
8,12
D16S539
11
D18S51
21
D19S433
14,15
D21S11
29,30
D2S1338
20
D3S1358
18
D5S818
11,12
D7S820
8
D8S1179
13,14
FGA
19,23
Penta D
8,9,12
Penta E
15,17
TH01
6,9.3
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

The proteomic landscape of triple-negative breast cancer.";

Irie H.Y., Lee S.-I., Blau C.A., Villen J.

Cell Rep. 11:630-644(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Proteomic portrait of human breast cancer progression identifies novel prognostic markers.

Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.

Cancer Res. 72:2428-2439(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Androgen sensitivity of the new human breast cancer cell line MFM-223.";

Schulz K.-D.

Cancer Res. 51:5722-5727(1991).

Cell lines from human breast.";

Leibovitz A.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).